SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Momenta Pharmaceuticals Inc.
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
3027 64 0 MNTA
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2102MNTA ‘ReadMeFirst’ updated: <i>3Q09 financial results and CC transcript; DewDiligence_on_SI-11/7/2009
2101seekingalph: Momenta Pharmaceuticals, Inc. (MNTA) Q3 2009 Earnings Call Transcrmopgcw-11/7/2009
2100The Lovenox plot may have thickened: siliconinvestor.comDewDiligence_on_SI111/3/2009
2099Good point. I can't think of one, but sad to say I didn't take advantagetom pope-10/16/2009
2098Options - another month, another 6-7%. Not quite the 10% monthly that it yieldeRocky9-10/16/2009
2097Can't say that I disagree. 5 years seems to me to be fair, and as stated, dBiotech Jim-10/15/2009
2096finance.yahoo.comArthur Radley-10/15/2009
2095Seeking Alpha: Momenta Pharma's M-Enoxaparin: Timing Uncertain, Approval Likmopgcw-10/10/2009
2094Are you fond of Mahler?tom pope-10/8/2009
2093Closing the Book on Robyn Karnauskas… I hesitate to post this because I may be DewDiligence_on_SI-10/8/2009
2092Whatever she may have said on the call, that's not what's in print in herkrw-10/7/2009
2091Jim, my post recites what Karnauskas actually said on the recent CC. Moreover, IDewDiligence_on_SI-10/7/2009
2090Ok. But you have your facts wrong about her numbers. Our $15 price target is brkrw-10/7/2009
2089That is so bizarre and air headed that there HAS to be an explanation buried in tom pope-10/7/2009
2088The market is inefficient, all right, but rarely to the extent that Karnauskas&#DewDiligence_on_SI-10/7/2009
2087<<Karnauskas says MNTA would be worth $18/sh if the Lovenox program did notnsaf-10/7/2009
2086<i>>[The DB analysts] are quite good actually and very thorough.<<DewDiligence_on_SI210/7/2009
2085MNTA ‘ReadMeFirst’ updated: <i>new valuation analysis for the single-geneDewDiligence_on_SI-10/4/2009
2084I fully agree...Solvay has a truly balanced line-up in their approved drugs. TriArthur Radley19/28/2009
2083<i>>…considering that ABT is spending several Bs today and the stock isDewDiligence_on_SI-9/28/2009
2082I've had the impression, partially from Bulbaman's tracking of the sectoIan@SI-9/28/2009
2081I agree that M&A isn't the only driver in the sector, but considering thArthur Radley-9/28/2009
2080Art, As we approach Q end, I suspect that most of the bearish fund managers areIan@SI-9/28/2009
2079Nice to see the block share activity...volume is up nicely and several blocks ofArthur Radley-9/28/2009
2078MNTA’s underwriter exercised the over-allotment option, which gives MNTA about DewDiligence_on_SI-9/28/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News